Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women
Authors:
- Roksana Mbbs KarimRKRoksana Mbbs Karim
- Mary Md CushmanMCMary Md Cushman
- Roger A. LoboRLRoger A. Lobo
- 1 July 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Menopause
- Vol. 17 (4) , 785-790
Abstract
Objective: Hormone therapy has been shown to reduce markers of vascular inflammation in postmenopausal women. C-reactive protein (CRP), a marker of generalized inflammation, is raised by oral estradiol therapy (ET). It is not known how sex hormone concentrations relate to the markers of inflammation in postmenopausal women taking or not taking hormone therapy. Methods: This observational study includes postmenopausal women participating in the Estrogen in the Prevention of Atherosclerosis Trial. Multiple measures of serum sex hormone and sex hormone-binding globulin (SHBG) levels from 107 postmenopausal women taking oral ET and 109 taking placebo for 2 years were correlated with markers of inflammation over the same time period using generalized estimating equations. Results: Levels of soluble intercellular adhesion molecule-1 were significantly inversely associated with estrone (P = 0.05), total and free estradiol (P = 0.008 and 0.02, respectively), and SHBG (P = 0.03) only among oral ET users. Serum homocysteine levels were also inversely associated with estrone (P = 0.001) and total and free estradiol (P = 0.0006 and 0.0009, respectively) in ET-treated women only. No such associations were observed among women taking placebo. CRP was positively associated with estrogens and SHBG among women taking oral ET but inversely associated with SHBG among the placebo group. Conclusions: The inverse associations of estrogens with soluble intercellular adhesion molecule-1 and homocysteine support an anti-inflammatory property of estrogen, which was observed only at pharmacological levels in postmenopausal women. The positive associations between estrogens and CRP in the ET-treated women can be explained by the first-pass hepatic effect rather than a proinflammatory response.Keywords
This publication has 39 references indexed in Scilit:
- Inflammatory Markers and Progression of Subclinical Atherosclerosis in Healthy Postmenopausal Women (from the Estrogen in the Prevention of Atherosclerosis Trial)The American Journal of Cardiology, 2008
- Relationship between Serum Levels of Sex Hormones and Progression of Subclinical Atherosclerosis in Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 2008
- Association of Endogenous Hormones with C-reactive Protein, Fibrinogen, and White Blood Count in Post-menopausal WomenEuropean Journal of Epidemiology, 2005
- Effect of oral conjugated equine estrogen combined with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal womenFertility and Sterility, 2005
- Sex Hormone Levels and Risk of Cardiovascular Events in Postmenopausal WomenCirculation, 2003
- Increased Levels of C-Reactive Protein After Oral Hormone Replacement Therapy May Not Be Related to an Increased Inflammatory ResponseCirculation, 2003
- Elevated levels of homocysteine increase IL-6 production in monocytic Mono Mac 6 cellsBlood Coagulation & Fibrinolysis, 2000
- Postmenopausal Oral 17β-Estradiol Continuously Combined with Dydrogesterone Reduces Fasting Serum Homocysteine LevelsFertility and Sterility, 1998
- Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham StudyAmerican Heart Journal, 1987
- Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperatureThe Journal of Steroid Biochemistry and Molecular Biology, 1982